Article in The Lancet Infectious Diseases on RIVM research into Maternal pertussis vaccination Scientific journal The Lancet Infectious Diseases has published an article on RIVM research conducted into pertussis vaccination for pregnant women.
Vaccination against meningococcal disease starts for teens aged 14 to 18 This spring, about 860,000 young people in the Netherlands will receive an invitation for a vaccination against meningococcal disease.
Young people who use screens before sleeping have more sleep problems Young people (13-18 years) who use light-emitting screens daily in the hour before going to sleep have more sleep problems.
RIVM will make measurements around the Sint Maarten landfill From 21 January 2019, a team from RIVM will travel to Sint Maarten to make measurements and take samples at various locations around the landfill in Philipsburg.
Vaccination schedule for babies reviewed after introduction whooping cough vaccination for pregnant women Whooping cough is a dangerous disease for new born, unvaccinated babies. Starting at the end of 2019, the whooping cough vaccination will be offered nationwide to pregnant women.
Research: HPV vaccine is safe RIVM research shows no causal link between the vaccine against cervical cancer (HPV) and long-term fatigue symptoms in girls.
Teen vaccination against meningococcal disease starts From mid-September, young people born between 1 May and 31 December 2004 will receive an invitation for a vaccination against meningococcal disease.
Vaccination rate again drops slightly, HPV vaccination rate drops considerably The vaccination rate for vaccines included in the National Immunisation Programme has dropped slightly by about 1 percent.
New test has no added value in Lyme disease of the central nervous system Active Lyme disease of the central nervous system cannot be detected with an ELISpot test.
Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.